Pharming Group N.V. (PHARM.AS)

0,8980 +0,0215 (+2,45%) Börsenschluss: 05:35PM CEST

Pharming Group N.V.

Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 382

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sijmen de Vries M.B.A., M.D.	President, CEO & Executive Director	1,34M	N/A	1959
Mr. Jeroen Wakkerman	Chief Financial Officer	N/A	N/A	1969
Ms. Mireille Sanders M.Sc.	Chief Operations Officer	N/A	N/A	1968
Susanne Embleton	Investor Relations Manager	N/A	N/A	N/A
Mr. Ruud Van Outersterp	Chief Ethics & Compliance Officer	N/A	N/A	1964
Dr. Anurag Relan M.D., MPH	Chief Medical Officer	N/A	N/A	1972
Mr. Stephen Toor	Chief Commercial Officer & GM Americas	N/A	N/A	1971
Dr. Alexander Breidenbach M.B.A.	Chief Business Officer	N/A	N/A	1964
Dr. Bruno M. L. Giannetti	Consultant	N/A	N/A	1952

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Corporate Governance

Pharming Group N.V.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 1. Die grundlegenden Scores sind Audit: 7, Vorstand: 1, Shareholderrechte: 3, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.